protein

NLRP3

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NLRP3: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

4762Connections

21Hypotheses

17Analyses

50Outgoing

50Incoming

5Experiments

20Debates

Summary

NLRP3 is a protein involved in neurodegeneration research. Key relationships include: activates, interacts with, associated with. Associated with AD, ALI, ALS. Connected to 1473 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	NLRP3
Protein Type	Signaling Protein
Target Class	Signaling Protein
Function	In the healthy nervous system, NLRP3: - Provides innate immune surveillance - Responds to pathogen-associated molecular patterns (PAMPs) - Initiates inflammatory responses to cellular stress - Facilit
Mechanism of Action	Small molecule inhibitors targeting NLRP3 inflammasome assembly or activation
Druggability	Medium (0.51)
Clinical Stage	Approved
Molecular Weight	118 kDa
Pathways	Adaptive Immunity, Ampk Signaling, Amyloid, Apoptosis, Autophagy
UniProt ID	A0A7I2R3P8
GeneCards	NLRP3
Human Protein Atlas	NLRP3
IL-1β	Potent pro-inflammatory cytokine that sustains microglial activation, disrupts dopamine metabolism, and promotes additional α-synuclein aggregation
IL-18	Enhances IFN-γ production, driving Th1 polarization and chronic neuroinflammation
Associated Diseases	acute gouty arthritis, AD, Aging, ALI, Als
Known Drugs/Compounds	1,25(OH)2D, 1-deoxysphingolipids, Ams-17, Asiaticoside, Aucubin, Berberine
Interactions	ABCA1, ABCA7, ABCD3, ACE2, ACHE, acid sphingomyelinase
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	NLRP3/Mitophagy Coupling Modulation Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppr NLRP3 Inflammasome Chromatin Priming Through H3K27 (+3 more)
KG Connections	4762 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🧬 3D Structure Comparison — NLRP3 Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

7PZC — X-ray / Cryo-EM

🔮 AI Predicted Structure

Q96P20 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    subgraph Pathology["Pathology"]
        NLRP3["NLRP3"] -->|"associated with"| Inflammation["Inflammation"]
        TNF["TNF"] -->|"associated with"| NLRP3["NLRP3"]
        APOPTOSIS["APOPTOSIS"] -->|"associated with"| NLRP3["NLRP3"]
        AMYLOID["AMYLOID"] -->|"associated with"| NLRP3["NLRP3"]
        ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"associated with"| NLRP3["NLRP3"]
    end
    subgraph Signaling["Signaling"]
        NLRP3["NLRP3"] -->|"activates"| Inflammasome["Inflammasome"]
        NLRP3["NLRP3"] -.->|"inhibits"| Inflammation_1["Inflammation"]
        NLRP3["NLRP3"] -.->|"inhibits"| Als["Als"]
        NLRP3["NLRP3"] -.->|"inhibits"| Inflammasome_2["Inflammasome"]
        NLRP3["NLRP3"] -->|"activates"| Inflammation_3["Inflammation"]
        NLRP3["NLRP3"] -->|"activates"| Autophagy["Autophagy"]
        NLRP3["NLRP3"] -->|"activates"| Als_4["Als"]
        NLRP3["NLRP3"] -->|"activates"| Neuroinflammation["Neuroinflammation"]
        MICROGLIA["MICROGLIA"] -->|"activates"| NLRP3["NLRP3"]
        ROS["ROS"] -->|"activates"| NLRP3["NLRP3"]
    end
    style NLRP3 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style Inflammation fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Inflammasome fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Inflammation_1 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Inflammasome_2 fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Inflammation_3 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Autophagy fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als_4 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Neuroinflammation fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style TNF fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APOPTOSIS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AMYLOID fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style MICROGLIA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ROS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (2662)

Target	Relation	Type	Str
OXIDATIVE STRESS	activates	gene	1.00
NEUROINFLAMMATION	activates	gene	1.00
Oxidative Stress	activates	pathway	1.00
Inflammation	activates	disease	1.00
AUTOPHAGY	activates	gene	1.00
NF-ΚB	activates	gene	1.00
ASC	activates	protein	1.00
Nf-Κb	activates	pathway	1.00
Als	inhibits	disease	1.00
Autophagy	activates	pathway	1.00
Inflammasome	inhibits	pathway	1.00
CYTOKINES	activates	gene	1.00
MITOCHONDRIA	activates	gene	1.00
Neuroinflammation	activates	disease	1.00
Mitophagy	activates	pathway	1.00
PYROPTOSIS	activates	gene	1.00
Als	activates	disease	1.00
Apoptosis	activates	pathway	1.00
Pyroptosis	activates	pathway	1.00
Inflammation	inhibits	disease	1.00
TNF	inhibits	gene	1.00
Alzheimer	activates	disease	1.00
IL-6	inhibits	gene	1.00
UBIQUITIN	activates	gene	1.00
INFLAMMATION	regulates	gene	1.00
MITOPHAGY	activates	gene	1.00
Inflammation	associated_with	disease	1.00
Inflammasome	regulates	pathway	1.00
APOPTOSIS	activates	gene	1.00
MICROGLIA	activates	gene	1.00
ALZHEIMER	activates	gene	1.00
Neuroinflammation	inhibits	disease	1.00
Immune Response	activates	pathway	1.00
Inflammation	regulates	disease	1.00
INFLAMMATION	activates	gene	1.00
INFLAMMATION	inhibits	gene	1.00
Inflammasome	activates	pathway	1.00
CGAS	activates	gene	1.00
Nf-Κb	inhibits	pathway	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
CYTOKINES	inhibits	gene	1.00
TNF-Α	inhibits	gene	1.00
Mapk	activates	pathway	1.00
Inflammatory Cytokine Secretion	activates	process	0.95
NACHT domain	contains	protein	0.95
UPREGULATES	upregulates	entity	0.95
Necroinflammation	involved_in	process	0.95
Parkinson'S Disease	involved_in	disease	0.95
Aging	activates	disease	0.95
Sterile Neuroinflammation	associated_with	process	0.95

Incoming (2100)

Source	Relation	Type	Str
MICROGLIA	activates	gene	1.00
TNF	associated_with	gene	1.00
ROS	activates	gene	1.00
AMYLOID	associated_with	gene	1.00
IL-6	associated_with	gene	1.00
IL-1B	associated_with	gene	1.00
PARKINSON'S DISEASE	associated_with	disease	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
NF-KB	associated_with	protein	1.00
APOPTOSIS	associated_with	gene	1.00
NEUROINFLAMMATION	activates	gene	0.98
Damps	activates	compound	0.95
Litebamine	inhibits	compound	0.95
PCBMA-TAPP	activates	compound	0.95
Kaempferol	inhibits	compound	0.95
Berberine	inhibits	compound	0.95
sevoflurane	activates	drug	0.95
XHP	activates	drug	0.95
Aβ1-42	activates	biomarker	0.95
Pterostilbene	binds	compound	0.95
Irisin	inhibits	protein	0.95
Qingqi Liangying Formula	inhibits	drug	0.95
AUTOPHAGY	inhibits	process	0.95
Ams-17	inhibits	compound	0.95
P62	degrades	protein	0.95
Pterostilbene	inhibits	compound	0.95
Microglia	expressed_in	cell_type	0.95
TLR2	activates	gene	0.95
USP22	inhibits	protein	0.95
NLRP3 inflammasome inhibitors	inhibits	drug	0.93
Tnea Therapy	inhibits	drug	0.93
Alpha-Synuclein	activates	protein	0.93
AUTOPHAGY	regulates	entity	0.92
TFEB	promotes	protein	0.92
Cyclosporine A	upregulates	drug	0.92
Cerebral Ischemia-Reperfusion Injury	upregulates	disease	0.92
NF-κB	upstream_of	pathway	0.92
ARRB2	interacts_with	protein	0.92
ARRB2	modulates	protein	0.91
Hypoxic-Ischemic Brain Injury	upregulates	disease	0.91
GPR120	regulates	receptor	0.90
kaempferol	inhibits	compound	0.90
Macroautophagy	downregulates	process	0.90
ATP13A2	inhibits	gene	0.90
P62-Dependent Autophagy	mediates	pathway	0.90
Autophagy-Lysosome Pathway	degrades	pathway	0.90
NRF2	downregulates	entity	0.90
TREM2	inhibits	entity	0.90
SQSTM1	mediates	entity	0.90
Harmine	inhibits	compound	0.90

Targeting Hypotheses (21)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming	0.888	neurodegeneration	What are the mechanisms by which gut mic
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S	0.822	neurodegeneration	What are the mechanisms by which gut mic
NLRP3 Inhibition (H7): Downstream Inflammatory Reversal	0.780	neurodegeneration	Does restoring neuronal AMPK activity re
NLRP3 Inflammasome Lock Perpetuates Senescence-Associated In	0.720	neurodegeneration	What molecular mechanisms drive microgli
Galectin-3 deletion attenuates NLRP3 inflammasome activation	0.650	neuroscience	Lysosomal dysfunction and cathepsin leak

NLRP3/Mitophagy Coupling Modulation	0.646	Neuroinflammation	Immune atlas neuroinflammation analysis
C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macropha	0.640	neuroinflammation	What are the specific molecular mechanis
Selective cathepsin B inhibition prevents cathepsin leakage-	0.620	neuroscience	Lysosomal dysfunction and cathepsin leak
LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasom	0.617	neurodegeneration	How do perivascular cells specifically r
The most realistic translational use of physiological SCFAs	0.610	neurodegeneration	Do physiological concentrations of SCFAs
Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP	0.590	neurodegeneration	What are the optimal oxygen pressure, du
LAMP-2 replacement therapy prevents lysosomal membrane perme	0.580	neuroscience	Lysosomal dysfunction and cathepsin leak
CX3CR1-Negative Trem2-High Microglial Subset Mediates Female	0.570	neuroinflammation	How do regional, age, and sex-dependent
NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumul	0.566	developmental neurobiology	Do perinatal immune challenges create pe
NLRP3 Inflammasome Blockade as Upstream Intervention to Prev	0.566	neurodegeneration	Why have numerous phase 3 clinical trial
P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming	0.560	biomarkers	What biomarkers can reliably detect micr
Temporal NLRP3 Inhibition During SPP1-Driven Microglial Acti	0.551	neuroinflammation	What molecular mechanisms mediate SPP1-i
Physiological SCFAs may worsen alpha-synuclein pathology thr	0.550	neurodegeneration	Do physiological concentrations of SCFAs
Temporal NLRP3 Inhibition via SPP1-Mediated Mitophagy Enhanc	0.496	neuroinflammation	What molecular mechanisms mediate SPP1-i
TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inf	0.485	Neuroinflammation	Immune atlas neuroinflammation analysis
NLRP3 Inflammasome Suppression via Selective Caspase-1 Inhib	0.105	neurodegeneration	Neuroinflammation Biomarker Panel for Ea

Mentioning Analyses (17)

Scientific analyses that reference this entity

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

neurodegeneration | 2026-04-12 | 2 hypotheses Top: 0.682

Why have numerous phase 3 clinical trials failed despite advances in understandi

neurodegeneration | 2026-04-12 | 1 hypotheses Top: 0.566

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

neurodegeneration | 2026-04-11 | 0 hypotheses

Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular effica

clinical neurology | 2026-04-08 | 0 hypotheses

Can circadian interventions reverse microglial priming independent of sleep disr

chronobiology | 2026-04-08 | 0 hypotheses

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Molecular characterization of RBG-NLRP3 binding interaction	exploratory	atherosclerosis	0.900	0.00	purified proteins and molecula	proposed	N/A
Leukocyte gene expression analysis in COVID-19 patients	exploratory	COVID-19	0.900	0.00	human leukocytes from COVID-19	proposed	N/A
RBG effects on macrophage polarization and foam cell formation	exploratory	atherosclerosis	0.850	0.00	primary macrophages	proposed	N/A
Transcriptomic analysis of RBG effects on inflammatory gene expression	exploratory	atherosclerosis	0.800	0.00	ApoE-/- mice and cell cultures	proposed	N/A
NLRP3 Inflammasome Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (20)

Multi-agent debates referencing this entity

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

closed · Rounds: 4 · Score: 0.81 · 2026-04-23

What is the role of microglial synaptic pruning in Alzheimer's disease and other

closed · Rounds: 4 · Score: 0.68 · 2026-04-22

Lysosomal membrane permeabilization releasing cathepsins triggers NLRP3 inflamma

closed · Rounds: 4 · Score: 0.76 · 2026-04-22

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

closed · Rounds: 4 · Score: 0.75 · 2026-04-16

The debate identified a critical mechanistic gap between SCFA production by gut

closed · Rounds: 4 · Score: 0.70 · 2026-04-12

Why have numerous phase 3 clinical trials failed despite advances in understandi

closed · Rounds: 5 · Score: 0.67 · 2026-04-12

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 4 · Score: 0.69 · 2026-04-12

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

closed · Rounds: 4 · Score: 0.95 · 2026-04-11

Investigate how lipid raft composition (cholesterol metabolism, sphingolipids) c

closed · Rounds: 5 · Score: 0.93 · 2026-04-11

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 7 · Score: 0.91 · 2026-04-10

Related Research

Hypotheses and analyses mentioning NLRP3 in their description or question text

NLRP3

Understanding Entity Pages

Summary

Wiki Pages (21)

NLRP3 Inflammasome Hypothesis in Parkinson's Disease

NLRP3 Inflammasome Activation Pathway in Neurodegeneration

NLRP3 Inflammasome Pathway in Neurodegeneration

NLRP3 Senomorphic Cycling Therapy

NLRP3 Inflammasome Inhibitors for Parkinson's Disease

NLRP3-Coupled Senomorphic Cycling Therapy

NLRP3 Inflammasome Inhibitors for Neurodegenerative Diseases

NLRP3 Inhibitors for Neurodegeneration

NLRP3 Inflammasome Pathway in Alzheimer's Disease

NLRP3 Inflammasome Modulation for Parkinson's Disease

NLRP3 Inflammasome-Activated Microglia

Innate Immune Reprogramming: NLRP3 + CD47 Checkpoint Blockade

NLRP3 Inflammasome Therapeutics Investment Landscape

NLRP3 Inflammasome

CNS-Selective NLRP3 Inflammasome Inhibitor

NLRP3 Inflammasome Validation Study in Parkinson's Disease

NLRP3 Inflammasome Pathway in Neurodegeneration

NLRP3 (NLR Family Pyrin Domain Containing 3)

NLRP3 Inflammasome Inhibitors

NLRP3 Protein

NLRP3 Inhibitors in Parkinson's Disease: Research and Clinical Development

Pathway Diagram

Outgoing (2662)

Incoming (2100)

Targeting Hypotheses (21)

Mentioning Analyses (17)

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

Why have numerous phase 3 clinical trials failed despite advances in understandi

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular effica

Can circadian interventions reverse microglial priming independent of sleep disr

Lysosomal dysfunction and cathepsin leakage in Alzheimer disease progression

Senescent cell clearance as neurodegeneration therapy

Which cell types show the most significant expression changes for neurodegenerat

CRISPR-based therapeutic approaches for neurodegenerative diseases

Immune atlas neuroinflammation analysis in neurodegeneration

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Synaptic pruning by microglia in neurodegeneration

Synaptic pruning by microglia in early AD

4R-tau strain-specific spreading patterns in PSP vs CBD

Lipid raft composition changes in synaptic neurodegeneration

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (5)

Related Papers (0)

Debates (20)

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

What is the role of microglial synaptic pruning in Alzheimer's disease and other

Lysosomal membrane permeabilization releasing cathepsins triggers NLRP3 inflamma

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

The debate identified a critical mechanistic gap between SCFA production by gut

Why have numerous phase 3 clinical trials failed despite advances in understandi

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

Investigate how lipid raft composition (cholesterol metabolism, sphingolipids) c

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

Related Research

NLRP3/Mitophagy Coupling Modulation

C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages

Selective cathepsin B inhibition prevents cathepsin leakage-mediated NLRP3 infla

LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasome Activation and SPP

The most realistic translational use of physiological SCFAs is as an adjunct to

Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP3 inflammasome and s

LAMP-2 replacement therapy prevents lysosomal membrane permeabilization and down

CX3CR1-Negative Trem2-High Microglial Subset Mediates Female Resilience via Estr

NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumulation

NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplificati

P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming

Temporal NLRP3 Inhibition During SPP1-Driven Microglial Activation Windows

Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NLR

Temporal NLRP3 Inhibition via SPP1-Mediated Mitophagy Enhancement During Critica

TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome Regulation